Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. reported third-quarter 2026 net loss of $129.3 million, compared with $173.4 million a year earlier; non-GAAP adjusted net loss was $110.7 million versus $155.9 million. R&D expense was $101.9 million versus $141.2 million, and G&A expense was $24.6 million versus $28.2 million. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026.
Biohaven received $80 million from Ono on October 20, 2026, under an exclusive license for its MoDE IgG degrader portfolio. A further $20 million milestone payment is anticipated within a year of signing, and Biohaven is eligible for royalties of approximately 20% on licensed-territory net sales. Its global Kv7 license with SK Biopharmaceuticals provides $400 million in cash consideration: $350 million at closing and $50 million one year after closing, plus up to $150 million in development and regulatory milestones. The transaction remains subject to closing conditions.
The FDA accepted the Vyglxia resubmission for SCA and assigned a user fee goal date in the first quarter of 2027. A partial clinical hold pauses new opakalim enrollment only; dosing of more than 600 already randomized patients is allowed to continue, and RISE 3 topline data remain on track for the second half of 2026.
Biohaven Ltd. (BHVN) reported a third-quarter net loss of $129.3 million, compared with $173.4 million a year earlier; nine-month net loss was $397.1 million versus $593.3 million. Third-quarter research and development expense was $101.9 million, compared with $141.2 million. At September 30, 2026, cash and cash equivalents were $95.8 million, marketable securities were $65.4 million, and notes payable were $264.3 million.
Nine-month operating cash use was $341.9 million, compared with $478.8 million in 2025. Biohaven agreed to license its Kv7 platform to SK Biopharmaceuticals for a $400 million upfront fee, including $350 million at Closing and $50 million one year after Closing; the agreement is effective upon Closing. In October, Ono paid Biohaven $80 million upfront upon closing a license for rights to its MoDE degrader portfolio in specified Asian markets. A further $20 million depends on stability test results and Ono’s election to continue.
Biohaven Ltd. said the FDA accepted for review its resubmitted new drug application for Vyglxia (troriluzole) for SCA. The resubmission included new positive supportive analyses, and the FDA considers it a complete response to the November 4, 2025 action letter. The agency assigned a user fee goal date in the first quarter of 2027 and plans to convene its Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders; the anticipated meeting date will be forthcoming in the near term.
The goal date does not assure FDA action by then or approval. Troriluzole is an investigational drug and has not been approved for any indication in the United States.
Biohaven Ltd. (BHVN) entered into an exclusive regional license and collaboration with Ono Pharmaceutical Co., Ltd. for its MoDE pan-IgG degrader portfolio, led by BHV-1300 and including BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay $80 million upon closing and a further $20 million after receipt of specified stability test results if Ono elects to continue development and commercialization; the milestone was anticipated within a year after execution. Ono will also pay royalties of approximately 20% on licensed-product net sales, subject to specified reductions and adjustments.
Ono is generally responsible, at its own expense, for development, regulatory activities and commercialization in the licensed territory. Biohaven will continue specified studies, while Ono funds specified territory activities and shares specified costs of global clinical studies. Biohaven retains rights outside the territory, including the United States, Europe and China. BHV-1300 is in Phase 3 development for Graves' disease; Biohaven reported that a Phase 1b study showed reductions in the pathogenic TSH-receptor autoantibody, rapid normalization of free T3 and free T4, and symptom improvement.
Biohaven Ltd. (BHVN) reported that officer Kimberly Gentile, SVP, Clinical Operations, had a stock option grant reported in her name for 1,000 options to purchase Biohaven common shares at an exercise price of $12.34 per share, expiring September 15, 2036. The option was granted in connection with her son's employment and is held indirectly "By Son", with vesting in four equal installments on September 15 of 2026, 2027, 2028 and 2029, subject to his continuous service. Gentile disclaims beneficial ownership of all securities held by her son, and no Rule 10b5-1 trading plan is reported.
Biohaven Ltd. (BHVN) reports that the U.S. FDA issued a partial clinical hold on the BHV-7000 epilepsy program on September 4, 2026, pausing new patient enrollment while additional nonclinical studies further characterize a specific rodent metabolite.
Dosing continues for more than 600 already randomized patients across the BHV-7000 program, including BHV7000-303, which is fully enrolled, with topline data still expected in the second half of 2026. Over 1,200 participants have received BHV-7000 to date, and the safety profile has generally been described as safe and well-tolerated. BHV7000-302 and the open-label extension study will keep dosing but will not enroll new patients until the additional nonclinical data are available.
Separately, on August 26, 2026, Biohaven’s subsidiary Biohaven Bioscience Ireland Limited entered into a License Agreement under which SK Biopharmaceuticals will receive an exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform, including BHV-7000, subject to closing conditions including Hart-Scott-Rodino review. All clinical and nonclinical data, including metabolite characterization, were disclosed to SK Biopharmaceuticals before signing.
Biohaven Ltd. (BHVN) announced a strategic global license and collaboration under which its wholly owned subsidiary Biohaven Bioscience Ireland Limited will grant SK Biopharmaceuticals an exclusive, royalty-bearing worldwide license to Biohaven’s Kv7 ion channel platform, led by opakalim (BHV-7000), for epilepsy and other indications, effective upon closing.
SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash (including $350 million at closing and $50 million one year later) and up to $150 million in development and regulatory milestones, plus tiered royalties on global net sales of opakalim and other licensed products. SK Biopharmaceuticals will also reimburse certain pre-closing costs and fund agreed development activities while Biohaven completes ongoing Phase 2/3 RISE 2 and RISE 3 trials and prepares an NDA for opakalim.
In a related agreement, SK Biopharmaceuticals will assume up to $245 million in contingent milestone obligations and a mid‑single‑digit worldwide royalty owed under a prior acquisition agreement for the Kv7 platform. Closing is subject to antitrust review, including under the Hart‑Scott‑Rodino Act, and other customary conditions.
Biohaven Ltd. director John Yetimoglu reported initial indirect ownership of 6,250,000 Common Shares of Biohaven Ltd. These shares are held by Infinitum Cayman Master, Ltd., over which Mr. Yetimoglu, as Chief Investment Officer of Infinitum Partners, GP LLC, may be deemed to have voting and investment control. He disclaims beneficial ownership of the shares except to the extent of his pecuniary interests in that entity.
Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP, reports beneficial ownership of 7,660,280 Common Shares of Biohaven Ltd. This represents 5.1% of the outstanding Common Shares.
Woodline Partners has sole voting and sole dispositive power over 7,660,280 shares and no shared voting or dispositive power. The ownership percentage is based on 150,560,990 Common Shares outstanding as of April 30, 2026, as reported by Biohaven Ltd.
Biohaven Ltd. reported second quarter 2026 results alongside extensive R&D updates across immunology, epilepsy, obesity, neuroscience and oncology. The company highlighted its extracellular protein degrader platforms (MoDE and TRAP), including BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy, both showing deep, rapid reductions in disease-driving antibodies with favorable safety profiles and progressing toward or into pivotal trials in 2026.
Opakalim (BHV-7000) demonstrated durable seizure control across multiple epilepsy types with a differentiated tolerability profile, with topline Phase 2/3 focal epilepsy data expected in the second half of 2026. Oncology programs BHV-1530 and BHV-1510 continue under collaborations with Regeneron, while additional pipeline assets taldefgrobep alfa, BHV-8100 and BHV-8000 advance in obesity, neuroimmunology and Parkinson’s disease.
Financially, cash, cash equivalents, marketable securities and restricted cash totaled approximately $270.5 million as of June 30, 2026. Second quarter R&D expenses decreased to $100.8 million from $184.4 million a year earlier, and net loss narrowed to $137.3 million, or $0.91 per share, with non-GAAP adjusted net loss of $118.1 million, or $0.78 per share.